We are preparing the requested document. Please wait, this may take a while...!
|Antigen||CD86 Molecule (CD86) Antibodies|
|Epitope||AA 23-244 Alternatives|
|Conjugate||This CD86 antibody is un-conjugated Alternatives|
Cytometry by Time of Flight (CyTOF), Flow Cytometry (FACS), Neutralization (Neut), Western Blotting (WB)
|7 references available|
|Supplier||Log in to see|
Product Details anti-CD86 AntibodyTarget Details CD86 Application Details Handling References for anti-CD86 antibody (ABIN4899735) Images
|Specificity||Detects human B7-2/CD86 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) B7-1, recombinant mouse B7-2, recombinant rat B7-2, rhB7-H1, rhB7-H2, rhB7-H3, rhB7-H3b, rhB7-H4, or rhB7-L2 is observed.|
|Purification||Protein A or G purified from ascites|
|Sterility||0.2 μm filtered|
|Endotoxin Level||<0.10 EU per 1 μg of the antibody by the LAL method.|
|Immunogen||S. frugiperda insect ovarian cell line Sf 21-derived recombinant human B7-2/CD86, Ala23-His244, Accession # P42081|
|Plasmids, Primers & others|
Target Details CD86Product Details anti-CD86 Antibody Application Details Handling References for anti-CD86 antibody (ABIN4899735) Images back to top
|Alternative Name||B7-2/CD86 (CD86 Antibody Abstract)|
|Background||Alternative Names: Activation B7-2 antigen, B70, B72, B7-2, B7-2 antigen, B-lymphocyte activation antigen B7-2, BU63, CD28 antigen ligand 2, CD28LG2B7-2 antigen), CD86, CD86 antigen, CD86 Molecule, CTLA-4 counter-receptor B7.2, FUN-1, LAB72, MGC34413, T-lymphocyte activation antigen CD86|
|Pathways||TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation|
Application DetailsProduct Details anti-CD86 Antibody Target Details CD86 Handling References for anti-CD86 antibody (ABIN4899735) Images back to top
Western Blot 5 μg/mL
Flow Cytometry 0.25 μg/10^6 cells
Neutralization 0.5-2.5 μg/mL
|Restrictions||For Research Use only|
HandlingProduct Details anti-CD86 Antibody Target Details CD86 Application Details References for anti-CD86 antibody (ABIN4899735) Images back to top
|Reconstitution||Reconstitute at 0.5 mg/mL in sterile PBS.|
|Buffer||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Storage||4 °C,-20 °C,-80 °C|
|Storage Comment||Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt,-20°C to -70°C as supplied. 1 month,2°C to 8°C under sterile conditions after reconstitution. 6 months,-20°C to -70°C under sterile conditions after reconstitution.|
|Expiry Date||12 months|
References for anti-CD86 antibody (ABIN4899735)Product Details anti-CD86 Antibody Target Details CD86 Application Details Handling Images back to top
|Product cited in:||
Cavel, Shomron, Shabtay, Vital, Trejo-Leider, Weizman, Krelin, Fong, Wong, Amit, Gil: "Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor." in: Cancer research, Vol. 72, Issue 22, pp. 5733-43, 2012 Method employed by authors: Immunocytochemistry (ICC) (Sample species: Human).
Weissmüller, Semmler, Kalinke, Christians, Müller-Berghaus, Waibler: "ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation." in: Blood, Vol. 119, Issue 26, pp. 6268-77, 2012 Method employed by authors: Neutralization (Neut) (Sample species: Human).
El Fakhry, Alturaihi, Diallo, Merhi, Mourad: "Critical role of lipid rafts in CD154-mediated T cell signaling." in: European journal of immunology, Vol. 40, Issue 3, pp. 770-9, 2010 Method employed by authors: Flow Cytometry (FACS) (Sample species: Human).
Tso, Law, Tu, Chan, Lau: "Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells." in: Stem cells (Dayton, Ohio), Vol. 28, Issue 5, pp. 939-54, 2010 Method employed by authors: Neutralization (Neut) (Sample species: Human).
van der Vliet, Wang, Yue, Koon, Balk, Exley: "Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 180, Issue 11, pp. 7287-93, 2008 Method employed by authors: Neutralization (Neut) (Sample species: Human).
Sakthivel, Shively, Kakoulidou, Pearce, Lefvert: "The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm." in: Journal of internal medicine, Vol. 261, Issue 4, pp. 399-407, 2007 Method employed by authors: ELISA (ELISA) (Sample species: Human).
Hock, Patton, Budhia, Mannari, Roberts, McKenzie: "Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients." in: Leukemia, Vol. 16, Issue 5, pp. 865-73, 2002 Method employed by authors: ELISA (ELISA) (Sample species: Human).
ImagesProduct Details anti-CD86 Antibody Target Details CD86 Application Details Handling References for anti-CD86 antibody (ABIN4899735) back to top